Abstract 305P
Background
There is no evidence of effective follow-up for the detection of recurrent head and neck cancer (HNC). There are few reports on the frequency of relapse of platinum-resistant HNC in clinical practice. Local recurrence is often seen during the first two years during which follow-up computed tomography (CT)/magnetic resonance imaging is recommended. The occurrence rate of second cancer (SC) has been reported to be 14.5%.
Methods
We conducted a retrospective analysis to evaluate the clinical course in 374 patients with head and neck squamous cell carcinoma who underwent definitive treatment at our institute between January 1998 and November 2018. The observation period was until January 2019.
Results
Recurrence and/or metastasis of HNC (R/M HNC) and SC were seen in 128 and 34 patients, respectively. The sites of R/M HNC were the hypopharynx, oral cavity, and larynx in 30.5%, 21.9%, and 19.5% of the patients, respectively. The sites of SC were the larynx, hypopharynx, and oropharynx in 38.2%, 26.5%, and 20.6% of the patients, respectively. At the diagnosis of relapse of new cancer, 50% of patients with R/M HNC and 44.1% of those with SC were symptomatic. The most common symptom was pain, while other symptoms were swelling, loss of appetite, hoarseness, dysphagia, dyspnea, cough, and bleeding. The modality of detection of recurrence was highest with CT (60.2%), followed by endoscopy (14.1%) and medical examination (14.1%). The median time to recurrence was 6.9 (range, 0 − 141.8) months, with 75% of recurrences occurring within one year. Furthermore, 4.8% of the recurrences occurred after five years. Platinum-resistant relapse accounted for 26.6% of all patients with R/M HNC and 58.6% of the relapses occurred within six months. The median time to recurrence was 35.5 (range, 1.5 − 240.9) months, with 35.3% of the recurrences occurring after five years.
Conclusions
In clinical practice, it is important to note the timing of rescue treatment during the follow-up period, focusing on imaging and medical examinations and confirming the symptoms within one year of treatment for HNC. During the long-term follow-up, observation for suspected development of SC is necessary.
Clinical trial identification
.
Editorial acknowledgement
.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract